Vitamin Therapy in Concussion Management: A Randomized Control Trial

Thomas Jefferson University20 enrolled

Overview

The purpose of this study is to assess the efficacy of vitamin therapy in concussion when compared to placebo with respect to multiple endpoints including symptom severity, cognitive performance on computer based neuropsychological testing, post-concussion balance assessment, and post-concussion vestibular-oculomotor function.

To date, very little data exists on the use of vitamin supplementation to aid in the recovery of concussion. Data previously published shows potential benefit of certain vitamins in the management of migraine headache. These vitamins, Vitamin B2 (Riboflavin), Magnesium, Co-Enzyme Q-10, and Omega-3 fatty acids, at dosages described in the literature, are being used based on the migraine literature findings and anecdotal evidence to help treat complaints of headache in concussion management.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Concussion

Interventions

Experimental: Vitamin MixtureDIETARY_SUPPLEMENT

Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids

PlaceboDIETARY_SUPPLEMENT

Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.

Eligibility

Sex: ALLMin age: 11 YearsMax age: 22 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects ages 11-22 * Concussion within 7 days of enrollment * Presenting for treatment at Rothman Institute or Jefferson Concussion Center Exclusion Criteria: * Subjects with recent prior concussion within the past 30 days * Subjects with a history of moderate to severe TBI requiring hospitalization or resulting in prolonged symptoms (\>3weeks). * Subjects with known neurologic diagnosis associated with impaired cognitive function other that Attention Deficit Hyperactive Disorder or Attention Deficit Disorder. * Subjects with know allergy to algae, omega-3 fatty acid, or any component of the formulation. * Subjects currently requiring anticoagulants (ie- Warfarin), anti-platelets (ie- Aspirin, Plavix), or any non-steroidal anti-inflammatory drugs (ie- Ibuprofen, Naprosyn). * Subjects with known liver pathology or significantly elevated liver function tests (greater than 3 X normal). * Subjects with a current lower extremity injury that will affect postural stability testing. * Subjects who are pregnant and/or breast feeding.

Outcomes

Primary Outcomes

PCSI: Post-Concussion Symptom Inventory

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.